Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease

TÜZÜN, Erdem; içöz, sema; KÜÇÜKALİ, Cem İsmail; KÜRTÜNCÜ, Murat; ŞANLI, ELİF; YILMAZ, VUSLAT; AKBAYIR, Ece; Koral, Gizem; GÜNDÜZ, Tuncay; KARAASLAN, Zerrin; Timirci-Kahraman, Ozlem

doi:10.55730/1300-0144.5432

Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease

Zerrin KARAASLAN, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)

Elif ŞANLI, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)

Özlem TİMİRCİ KAHRAMAN, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Moleküler Tıp Anabilim Dalı, İstanbul, Türkiye)

Vuslat YILMAZ, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)

Ece AKBAYIR, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)

Gizem KORAL, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)

Sema İÇÖZ, (İstanbul Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Türkiye)

Tuncay GÜNDÜZ, (İstanbul Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Türkiye)

Cem İsmail KÜÇÜKALİ, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)

Murat KÜRTÜNCÜ, (İstanbul Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Türkiye)

Erdem TÜZÜN, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)

Diğer Yazarlar

Turkish Journal of Medical Sciences

0 0

Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1266 - 1273 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5432

Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease

Öz:

Background/aim: Clinical exacerbations characterized with neurological symptoms are observed in around 10% of Behçet’s disease (BD) patients and may culminate in severe disability. Although certain immunological factors have been associated with disease activity in neuro-Behçet’s disease (NBD), biomarkers for monitoring the clinical outcome of NBD have not been properly investigated. Materials and methods: Levels of neurofilament light chain (NFL), homeobox protein Hox-B3 (HoxB3), and YKL-40 were measured in cerebrospinal fluid (CSF) samples of 23 parenchymal (n = 16) and nonparenchymal (n = 7) NBD patients obtained during NBD attacks by ELISA. Parameters of clinical progression and outcome were assessed for an average follow-up period of 3.9 ± 1.3 years. Results: Parenchymal NBD patients showed elevated CSF levels of NFL, HoxB3, and YKL-40 as compared to nonparenchymal patients. NBD patients showing an increase in modified Rankin score (mRS) values during follow-up had significantly higher CSF NFL levels. Patients with relatively lower CSF NFL levels (<1000 ng/L) did not develop attacks or cognitive impairment interfering with daily life activities during follow-up. NFL levels correlated with disease duration and mRS at the last follow-up visit, while HoxB3 levels correlated with a number of attacks during follow-up. Conclusion: CSF level of NFL appears to predict the prospective somatic and cognitive disability in NBD patients and may thus be potentially used as a biomarker of clinical outcome in this disease.

Anahtar Kelime: Neurofilament light hoxB3 ykl-40 neuro-Behçet prognosis

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Leccese P, Alpsoy E. Behçet’s Disease: An Overview of Etiopathogenesis. Frontiers in Immunology 2019; 10: 1067. doi: 10.3389/fimmu.2019.01067
2. Totsuka S, Hattori T, Yazaki M, Nagao K, Mizushima S. Clinicopathologic studies on neuro-Behçet’s disease. Folia Psychiatrica et Neurologica Japonica 1985; 39: 155-166. doi: 10.1111/j.1440-1819.1985.tb02899.x
3. Arai Y, Kohno S, Takahashi Y, Miyajima Y, Tsutusi Y. Autopsy case of neuro-Behçet’s disease with multifocal neutrophilic perivascular inflammation. Neuropathology: Official Journal of the Japanese Society of Neuropathology 2006; 26: 579-585. doi: 10.1111/j.1440-1789.2006.00734.x
4. Kürtüncü M, Tüzün E, Akman-Demir G. Behçet’s Disease and Nervous System Involvement. Current Treatment Options in Neurology 2016; 18: 19. doi: 10.1007/s11940- 016-0405-6
5. Acar-Özen NP, Tuncer A. Prognosis of Neuro-Behçet’s Syndrome. In: Tüzün E, Kürtüncü M (editors): Neuro-Behçet’s Disease. Springer, Cham 2021: 151-162.
6. Takahashi S, Sanjo N, Miyamoto S, Hattori T, Oyama J et al. Width of the third ventricle as a highly-sensitive biomarker in chronic progressive neuro-Behçet’s disease. Journal of the Neurological Sciences 2020; 421: 117284. doi: 10.1016/j.jns.2020.117284
7. Liu J, Yan D, Wang Z, Yang Y, Zhang S et al. Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet’s syndrome: case series and literature review. Therapeutic Advances in Musculoskeletal Disease 2020; 12: 1759720X20971908. doi: 10.1177/1759720X20971908
8. Ben Dhifallah I, Borhani-Haghighi A, Hamzaoui A, Hamzaoui K. Decreased Level of IL-37 Correlates Negatively with Inflammatory Cytokines in Cerebrospinal Fluid of Patients with Neuro-Behçet’s Disease. Iranian Journal of Immunology: IJI 2019; 16: 299-310. doi: 10.22034/IJI.2019.80281
9. Sumita Y, Murakawa Y, Sugiura T, Wada Y, Nagai A et al. Elevated BAFF levels in the cerebrospinal fluid of patients with neuro-Behçet’s disease: BAFF is correlated with progressive dementia and psychosis. Scandinavian Journal of Immunology 2012; 75: 633-640. doi: 10.1111/j.1365-3083.2012.02694.x
10. Akman-Demir G, Tüzün E, İçöz S, Yeşilot N, Yentür SP et al. Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine 2008; 44: 373-376. doi: 10.1016/j.cyto.2008.10.007
11. Ramani S, Berard JA, Walker LAS. The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review. Journal of the Neurological Sciences 2021; 420: 117229. doi: 10.1016/j.jns.2020.117229
12. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L et al. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery, and Psychiatry 2019; 90: 870-881. doi: 10.1136/jnnp-2018-320106
13. Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-1093. doi: 10.1093/brain/awq035
14. Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K et al. The glial marker YKL-40 is decreased in synucleinopathies. Movement Disorders: Official Journal of the Movement Disorder Society 2013; 28: 1882-1885. doi: 10.1002/mds.25589
15. Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis 2015; 21: 1251-1261. doi: 10.1177/1352458514561906
16. Lopalco G, Lucherini OM, Lopalco A, Venerito V, Fabiani C et al. Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease. Frontiers in Immunology 2017; 8: 200. doi: 10.3389/ fimmu.2017.00200
17. Bilen H, Altınkaynak K, Şebin E, Aksoy H, Akçay F. Serum YKL-40 and MDA levels in Behçet disease. The Journal of the Pakistan Medical Association 2016; 66: 1299-1302
18. Seo J, Ahn Y, Zheng Z, Kim BO, Choi MJ et al. Clinical significance of serum YKL-40 in Behçet disease. The British Journal of Dermatology 2016; 174: 1337-1344.
19. Timirci-Kahraman O, Karaaslan Z, Tüzün E, Kürtüncü M, Baykal AT et al. Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid. Acta Neurologica Belgica 2019; 119: 101-111. doi: 10.1007/s13760-018-0954-4
20. Tamam Y, Güneş B, Akbayır E, Kızılay T, Karaaslan Z et al. CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 2020; 48: 102697. doi: 10.1016/j.msard.2020.102697
21. Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ et al. Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation. Immunity 1997; 6: 13-22. doi: 10.1016/ s1074-7613(00)80238-1
22. Lindblad O, Chougule RA, Moharram SA, Kabir NN, Sun J et al. The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochemical and Biophysical Research Communications 2015; 467: 742-747. doi: 10.1016/j.bbrc.2015.10.071
23. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990; 335:1078-1080.
24. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. Journal of Neuroinflammation 2010; 7: 34. doi: 10.1186/1742-2094-7-34
25. Uğurel E, Erdağ E, Küçükali Cİ, Olcay A, Şanlı E et al. Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-Behçet’s Disease. In Vivo 2019; 33: 1493- 1497. doi: 10.21873/invivo.11629
26. Kim EH, Park MJ, Park S, Lee ES. Increased expression of the NLRP3 inflammasome components in patients with Behçet’s disease. Journal of Inflammation (London, England) 2015; 12: 41. doi:10.1186/s12950-015-0086-z
27. Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A et al. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology 2019; 266: 2157-2163. doi: 10.1007/s00415-019-09398-7
28. Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Multiple Sclerosis 2020; 26: 1670-1781. doi: 10.1177/1352458519881428
29. Moses Alder N, Fisher M, Yazıcı Y. Behçet’s syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clinical and Experimental Rheumatology 2008; 26: S110-113.
30. Mumcu G, İnanç N, Yavuz S, Direskeneli H. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet’s disease. Clinical and Experimental Rheumatology 2007; 25: S27-33.
31. Gündüz T, Kürtüncü M, Matur Z, Tüzün E, Limon U et al. Laboratory and clinical correlates of brain atrophy in Neuro- Behçet’s disease. Journal of the Neurological Sciences 2020; 414: 116831. doi: 10.1016/j.jns.2020.116831
32. Yeşilot N, Shehu M, Öktem-Tanör O, Serdaroğlu P, Akman- Demir G. Silent neurological involvement in Behçet’s disease. Clinical and Experimental Rheumatology 2006; 24 (5 Suppl 42): S65-70.
33. Barros C, Fernandes A. Linking Cognitive Impairment to Neuroinflammation in Multiple Sclerosis using neuroimaging tools. Multiple Sclerosis and Related Disorders 2020; 47: 102622. doi: 10.1016/j.msard.2020.102622
34. Jiang D, Gong F, Ge X, Lv C, Huang C et al. Neuron-derived exosomes-transmitted miR-124-3p protect traumatically injured spinal cord by suppressing the activation of neurotoxic microglia and astrocytes. Journal of Nanobiotechnology 2020; 18: 105. doi: 10.1186/s12951-020-00665-8

APA	KARAASLAN Z, ŞANLI E, Timirci-Kahraman O, YILMAZ V, AKBAYIR E, Koral G, içöz s, GÜNDÜZ T, KÜÇÜKALİ C, KÜRTÜNCÜ M, TÜZÜN E (2022). Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. , 1266 - 1273. 10.55730/1300-0144.5432
Chicago	KARAASLAN Zerrin,ŞANLI ELİF,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,AKBAYIR Ece,Koral Gizem,içöz sema,GÜNDÜZ Tuncay,KÜÇÜKALİ Cem İsmail,KÜRTÜNCÜ Murat,TÜZÜN Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. (2022): 1266 - 1273. 10.55730/1300-0144.5432
MLA	KARAASLAN Zerrin,ŞANLI ELİF,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,AKBAYIR Ece,Koral Gizem,içöz sema,GÜNDÜZ Tuncay,KÜÇÜKALİ Cem İsmail,KÜRTÜNCÜ Murat,TÜZÜN Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. , 2022, ss.1266 - 1273. 10.55730/1300-0144.5432
AMA	KARAASLAN Z,ŞANLI E,Timirci-Kahraman O,YILMAZ V,AKBAYIR E,Koral G,içöz s,GÜNDÜZ T,KÜÇÜKALİ C,KÜRTÜNCÜ M,TÜZÜN E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. . 2022; 1266 - 1273. 10.55730/1300-0144.5432
Vancouver	KARAASLAN Z,ŞANLI E,Timirci-Kahraman O,YILMAZ V,AKBAYIR E,Koral G,içöz s,GÜNDÜZ T,KÜÇÜKALİ C,KÜRTÜNCÜ M,TÜZÜN E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. . 2022; 1266 - 1273. 10.55730/1300-0144.5432
IEEE	KARAASLAN Z,ŞANLI E,Timirci-Kahraman O,YILMAZ V,AKBAYIR E,Koral G,içöz s,GÜNDÜZ T,KÜÇÜKALİ C,KÜRTÜNCÜ M,TÜZÜN E "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease." , ss.1266 - 1273, 2022. 10.55730/1300-0144.5432
ISNAD	KARAASLAN, Zerrin vd. "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease". (2022), 1266-1273. https://doi.org/10.55730/1300-0144.5432

APA	KARAASLAN Z, ŞANLI E, Timirci-Kahraman O, YILMAZ V, AKBAYIR E, Koral G, içöz s, GÜNDÜZ T, KÜÇÜKALİ C, KÜRTÜNCÜ M, TÜZÜN E (2022). Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences, 52(4), 1266 - 1273. 10.55730/1300-0144.5432
Chicago	KARAASLAN Zerrin,ŞANLI ELİF,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,AKBAYIR Ece,Koral Gizem,içöz sema,GÜNDÜZ Tuncay,KÜÇÜKALİ Cem İsmail,KÜRTÜNCÜ Murat,TÜZÜN Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences 52, no.4 (2022): 1266 - 1273. 10.55730/1300-0144.5432
MLA	KARAASLAN Zerrin,ŞANLI ELİF,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,AKBAYIR Ece,Koral Gizem,içöz sema,GÜNDÜZ Tuncay,KÜÇÜKALİ Cem İsmail,KÜRTÜNCÜ Murat,TÜZÜN Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1266 - 1273. 10.55730/1300-0144.5432
AMA	KARAASLAN Z,ŞANLI E,Timirci-Kahraman O,YILMAZ V,AKBAYIR E,Koral G,içöz s,GÜNDÜZ T,KÜÇÜKALİ C,KÜRTÜNCÜ M,TÜZÜN E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences. 2022; 52(4): 1266 - 1273. 10.55730/1300-0144.5432
Vancouver	KARAASLAN Z,ŞANLI E,Timirci-Kahraman O,YILMAZ V,AKBAYIR E,Koral G,içöz s,GÜNDÜZ T,KÜÇÜKALİ C,KÜRTÜNCÜ M,TÜZÜN E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences. 2022; 52(4): 1266 - 1273. 10.55730/1300-0144.5432
IEEE	KARAASLAN Z,ŞANLI E,Timirci-Kahraman O,YILMAZ V,AKBAYIR E,Koral G,içöz s,GÜNDÜZ T,KÜÇÜKALİ C,KÜRTÜNCÜ M,TÜZÜN E "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease." Turkish Journal of Medical Sciences, 52, ss.1266 - 1273, 2022. 10.55730/1300-0144.5432
ISNAD	KARAASLAN, Zerrin vd. "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease". Turkish Journal of Medical Sciences 52/4 (2022), 1266-1273. https://doi.org/10.55730/1300-0144.5432